Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHongjia ZhuShanghai Genon Biological Products (China)HGHongfei GuChina Mobile (China)XLXiangping LiTianjin University

Discussion

Loading...

Member takes

Implication

Clinical findings suggest glofitamab use before leukapheresis impairs CAR-T efficacy and T-cell activation in R/R DLBCL patients.

Key Points

  • This research investigates the impact of glofitamab on CAR-T therapy outcomes in R/R DLBCL patients.
  • Compared outcomes of R/R DLBCL patients who received glofitamab before leukapheresis with those who did not.
  • Assessed CAR-T manufacturing parameters, post-infusion efficacy, and cellular kinetics.
  • Conducted immunophenotyping of apheresis products to evaluate T-cell subsets.
  • Exposed group showed 33% overall response rate (ORR) versus 80% in unexposed group (p=0.026).
  • Glofitamab exposure identified as independent risk factor for reduced ORR (OR=0.08).
  • Increased Treg and PD-1+ T-cell proportions were noted in exposed patients.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddbdhttps://doi.org/10.1182/blood-2025-2382
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025 · 1 citations
  2. 2Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025
  3. 3Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  4. 4TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma2026
  5. 5Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort2026